In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices and more. Watch more here: https://bit.ly/3SuqtHr
Practical Dermatology’s Post
More Relevant Posts
-
Start slow, urges Shanna M. Miranti, MPAS, PA-C, a Board-certified Physician Assistant at Riverchase Dermatology in Naples, FL. Isotretinoin dosing schedules vary by prescriber. Ms. Miranti starts at 40mg taken once daily in the morning and encourages her patients to take isotretinoin with a healthy fat to maximize absorption. Starting low and keeping patients on topical therapy for the first month will also help prevent purging, she adds. https://lnkd.in/dDnuXHSz
-
International Fellow of American Academy of Dermatology. Board certified Specialist Dermatologist currently working in Dubai at Mubadala Health medical and day surgery center, at sunset mall, Jumeirah 3.
Interesting read.
Most viewed in the last 7 days from JAMA Dermatology: Is antihypertensive drug use associated with diagnoses of eczematous dermatitis among older adults? https://ja.ma/4bZHxvM
-
-
Most viewed in the last 7 days from JAMA Dermatology: What is the clinical effectiveness of dupilumab for long-term use in patients with atopic dermatitis, and what are reasons to discontinue dupilumab treatment? https://ja.ma/4fPcky7
-
-
Members - International Alliance of Patients' Organizations (IAPO) has recently launched a survey to uncover unmet patient needs worldwide (including dermatology patients) and you are invited to be part of it. It's a quick 15-minute survey, and your input can make a world of difference. Hurry, the survey is open until January 15th! Scan the QR code or head to the link below to contribute to this important cause: https://lnkd.in/dhpUcUX2 #UnmetPatientNeeds #PatientVoice #GlobalHealthSurvey #PatientOrganization
-
-
Director of Business Development at Carelon Research | HEOR | Safety & Epi | Clinical Research | PCR
If you missed this poster at the conference, please reach out to me to learn more about this incredible study.
This weekend our eposter (#53102) on atopic dermatitis treatments before and after initiation of ruxolitinib cream: Analysis of a US payer claims database, was featured at the American Academy of Dermatology's annual meeting: https://bit.ly/49VyWtL. #AAD
-
-
CEO @ Sibel Health | Ruth K. Freinkel MD Professor @ Northwestern University | Physician Engineer | Digital Health Leader | Board Certified Dermatologist | Head of the Medical Advisory Board - Geologie
Patient-reported outcomes tell part of the story— objective data fills the gaps. Asking patients how they feel will always be important. But, responses are too easily influenced to be fully reliable. Our sensors quantify nocturnal scratch with 93% sensitivity and 99% specificity against infrared camera labels in adults with atopic dermatitis published in the Journal of the American Academy of Dermatology. Pair this with patient voices, and better trial outcomes will quickly follow. PS - Read the full articile here: https://lnkd.in/gF_C6iSm
-
-
Test your knowledge, expand your skillset, or prepare for board certification with our free peer-scored board review challenge. Over 500 multiple choice questions dive deep and thoroughly into the field of dermatology: https://lnkd.in/ehSVaiNE
-
-
The May supplement of Dermatology Times is live! Download now and explore insights from a panel of 5 experts as they discuss unmet needs in nonsteroidal topical treatment for atopic dermatitis, data from the SCRATCH-AD and TRuE-AD3 studies, and more. https://lnkd.in/gD8-SyGi
-
-
New Congress Report from the 2024 American Academy of Dermatology (#AAD) Annual Meeting! In this report, 2022 #IPCFellow Lucas Galimany has compiled 36 summaries of presentations focusing on #psoriasis, including # IPC's Symposium: The Comprehensive Care of Psoriasis. Don't miss the latest and most intriguing updates on psoriasis from #AAD2024. Read the summary or download the full report: https://lnkd.in/g36YmpR3 #IPCCongressReport #PsoriasisNews
-
-
NEW PUBLICATION: Dermatology and Therapy published new study results of anti-IL-13 therapy from ADvocate 1 & 2, exploring stability of itch and skin responses at 52 weeks in patients with moderate-to-severe atopic dermatitis. View full publication here: https://e.lilly/3yBlyxu #AtopicDermatitis
-
